Concepedia

Publication | Open Access

PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15

105

Citations

51

References

2020

Year

Abstract

Blockade of programmed death-1 (PD-1) reinvigorates exhausted CD8<sup>+</sup> T cells, resulting in tumor regression in cancer patients. Recently, reinvigoration of exhausted CD8<sup>+</sup> T cells following PD-1 blockade was shown to be CD28-dependent in mouse models. Herein, we examined the role of CD28 in anti-PD-1 antibody-induced human T cell reinvigoration using tumor-infiltrating CD8<sup>+</sup> T cells (CD8<sup>+</sup> TILs) obtained from non-small-cell lung cancer patients. Single-cell analysis demonstrated a distinct expression pattern of CD28 between mouse and human CD8<sup>+</sup> TILs. Furthermore, we found that human CD28<sup>+</sup>CD8<sup>+</sup> but not CD28<sup>-</sup>CD8<sup>+</sup> TILs responded to PD-1 blockade irrespective of B7/CD28 blockade, indicating that CD28 costimulation in human CD8<sup>+</sup> TILs is dispensable for PD-1 blockade-induced reinvigoration and that loss of CD28 expression serves as a marker of anti-PD-1 antibody-unresponsive CD8<sup>+</sup> TILs. Transcriptionally and phenotypically, PD-1 blockade-unresponsive human CD28<sup>-</sup>PD-1<sup>+</sup>CD8<sup>+</sup> TILs exhibited characteristics of terminally exhausted CD8<sup>+</sup> T cells with low TCF1 expression. Notably, CD28<sup>-</sup>PD-1<sup>+</sup>CD8<sup>+</sup> TILs had preserved machinery to respond to IL-15, and IL-15 treatment enhanced the proliferation of CD28<sup>-</sup>PD-1<sup>+</sup>CD8<sup>+</sup> TILs as well as CD28<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> TILs. Taken together, these results show that loss of CD28 expression is a marker of PD-1 blockade-unresponsive human CD8<sup>+</sup> TILs with a TCF1<sup>-</sup> signature and provide mechanistic insights into combining IL-15 with anti-PD-1 antibodies.

References

YearCitations

Page 1